RhoVac ApS | LinkedIn

Press Release

RhoVac plans for a fully guaranteed convertible loan rights issue, to finance activities following a successful clinical phase IIb study outcome

Feb 09, 2022

RhoVac AB (”RhoVac”) announces today, February 9, 2022, that the Board of Directors intends to decide on execution of a preferential rights issue of a convertible loan (“the Planned Offer”) of approx. 25 M SEK in March/April 2022. The Planned Offer is via written agreement fully guaranteed, free of charge, by RhoVac’s largest shareholder M2 Asset Management AB. The objective of the Planned Offer is to further ensure that the company, given positive primary outcome results of the study, has the proper financial strength to negotiate and conclude optimally on the clinical phase IIb study follow-up. The phase IIb results are expected May/June 2022 and partakers of The Planned Offer would have the option to convert the loan to shares after that at a price of 40 SEK/share in June/July. Fully converted, the shares issued would correspond to 3.2 % of total shares.

The Planned Offer is to be extended to all shareholders, and is fully guaranteed by RhoVac’s largest shareholder, Rutger Arnhult, through his company M2 Asset Management AB. The guarantor receives no compensation for the guarantee commitment. The convertible loan yields an annual fixed interest rate of 10 % and if the convertible loan is not converted into shares, it will be paid back in full within one year. The Planned Offer is thus intended to provide participants with the right, but not the obligation, to convert the loan to shares at a price of 40 SEK/share in June/July of 2022, after the primary outcome of the clinical phase IIb study is known. The solution is specifically designed to offer existing shareholders a possibility of benefitting from an expected valuation upside, on the back of successful study outcomes, by having the ability to convert the loan to shares at the pre-arranged 40 SEK/share price, no matter what the stock price is after the primary results of the study are presented, presumably in May/June 2022. For the company, the benefit is that this precludes a potential need to raise money later, while negotiating and executing on the phase IIb study follow-up, on the back of positive study results. A preliminary timeline for the convertible loan issue is outlined in the attached appendix.

RhoVac started the clinical phase IIb trial (BRaVac) with the company’s drug candidate, RV001 (onilcamotide), late 2019, in prostate cancer patients with a biochemical recurrence (a rise in PSA) after curative intent therapy. In November of 2020, RhoVac was awarded Fast Track Designation by the FDA for its drug candidate in this cancer indication. RhoVac currently estimates finalising the study and presenting primary outcomes by May/June 2022. The objective of the study is to show that RV001 (onilcamotide) can significantly prevent or delay progression in this large patient group for whom no standard therapy is available today. On the back of positive phase IIb results, RhoVac intends to negotiate an acquisition or license deal with a company that has the best possible capabilities for phase III development in prostate cancer, for potential development in other areas, and for a successful launch of the drug.

RhoVac CEO, Anders Månsson, comments: “There is unanimous agreement in the Board that it is best to strengthen the cash position of the company somewhat before starting the negotiations and executing on the phase IIb follow-up that would follow a positive study outcome. In doing that, we want to offer shareholders the possibility of partaking further of an expected valuation increase that would come from positive phase IIb study results, by offering the option of converting the loan to shares, at 40 SEK/share, after phase IIb results are in, and irrespective of the market price of the stock at that time. As such, we suggest it is a win-win solution for the company and its shareholders alike.”


This disclosure contains information that RhoVac is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-02-2022 08:38 CET.

On RhoVac AB

RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has passed the early stages of development. In 2018, the first clinical trial (phase I / II) was completed in prostate cancer, demonstrating that RV001 has good safety and is well tolerated, and that the drug provides the expected immune response that will exert its effect on the cancer cells. The strong immune response has also been shown to last over time. Therefore, RhoVac has launched a clinical phase IIb trial that has recruited more than 180 prostate cancer patients. The study will close in the first half of 2022, and it is designed to show, with statistical significance, the effect of RV001 in preventing disease progression in prostate cancer after surgery or radiation to the primary tumour. RhoVac is listed on Spotlight, Sweden, a Multilateral Trading Facility (MTF) since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com. RhoVac is analysed by EDISON Group as well as by Swedish “Analysguiden”. Links to these analyses are found below:

Edison:                          https://www.edisongroup.com/publication/phase-iib-bravac-study-results-in-h122/30057
Analysguiden:              https://www.aktiespararna.se/analysguiden/Hitta-Bolag/rhovac/rhovac-ab

On BRaVac

BRaVac is a randomized, placebo controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatment. The clinical phase IIb study is an international, multi-centre study, has recruited over 180 patients in six European countries (Denmark, Finland, Sweden, Belgium, Germany, and United Kingdom) and the US. After treatment, patient in the study will enter an Extended Follow-Up that could last until Q4 2022.